Chiesi Pharmaceuticals Revenue and Competitors

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research centres, the Group has over 2,800 employees. The three research and development sites (Italy, France and United States) employ more than 300 people, while the three manufacturing facilities employ about 600 people. Chiesi's technologies and products are available in over 50 countries through a strategic alliances network of international pharmaceutical groups developed both on a global and local scale. Group turnover reached 565 million Euros in 2005. Historically, the continuous development of the Company has been based on strategic planning for innovation, internationalisation, socially compatible economical values, and use of effective organizational structures. The pharmaceutical scenario is rapidly changing. Emerging markets are growing much faster than mature economies even in healthcare spending. Our final stakeholders, the patients, are becoming more and more important in the evaluation of our products in terms of perceived efficacy. The controls and pressures on the expenditure level for medicines by those who pay, whether public or private, are constantly increasing. As a consequence, the success of our future products will be measured increasingly on two parameters: perceived effectiveness and pharmaco-economic advantages. To continue obtaining successful results, the Chiesi Group wants to achieve two goals: firstly, to continue dimensional growth, reaching critical mass in all the markets in which we are present and secondly, to develop new products in our therapeutic areas of expertise, that are perceived as effective by our customers, providing them with a closer and more complete level of service. The more the Group grows, the more new financial resources we will have for our future growth and the more we will focus our research on developing novel drugs for the treatment of respiratory, cardiovascular and orphan diseases such as respiratory distress syndrome and cystic fibrosis. We are convinced that our company can accept the challenge of the future with a well-founded optimism. We have already shown a relevant ability to attract valuable human resources: some of our achievements in R & D, in production technology or commercial growth, are well recognised and provide evidence of our competitiveness in the international marketplace. This is also the outcome of a number of longstanding investments. In the last three years we spent 210 million Euro in R & D and 63 million in fixed and immaterial technological investments: a total amount of more than 270 million Euro. We plan to spend 350 million Euro in R & D and almost 100 million in fixed and immaterial technological investments over the next three years: a combined amount of 450 million Euro. For these investments to be fruitful, we want the quality of our internal and external activities to be excellent. Our quality and effectiveness must be in line with that of our international competitors, in R & D, in sales and marketing and in services to our stakeholders. The strength of our company, gained through many years of effective management, will be the correct leverage for further growth in the marketplace. Although investments and excellence in our activities are essential, they are not enough: we also need the ethical values expressed by the principles that are at the basis of our Company's mission. Everyone in the company should demonstrate excellent moral values, at each level of responsibility, and thanks to the mutually recognised attitude towards innovation and excellence, this should produce an outstanding level of collaboration among us all: from Chiesi family members to the company executives and managers, from marketing and sales people to our external partners. This commitment is the foundation that the Chiesi Group is using to build a successful future for us all.